GILD Soars 3.60% to Close at $148.95 Following $7.8 Billion Acquisition Announcement

Gilead Sciences, Inc. Market Performance on February 27, 2026

Gilead Sciences, Inc. (ticker symbol: GILD) demonstrated a notable performance in the U.S. stock market on February 27, 2026. The stock opened at $143.56 and closed at $148.95, marking an increase of $5.18, or approximately 3.60%, from the previous closing price of $143.77. During the trading session, the stock reached an intraday high of $150.00 and a low of $143.37. The total trading volume for the day was approximately 11.1 million shares, indicating strong investor interest.

Market Context and Performance

The upward movement in Gilead's stock price was influenced by a combination of corporate announcements and overall market sentiment relating to the company's developments. Analysts observed that Gilead’s stock outperformed the broader healthcare sector, which also experienced positive movement but not to the same extent. Reports noted an intraday increase of approximately 3.72%, underscoring the stock’s strong relative performance.

Key News and Developments

1. Acquisition of Arcellx: Gilead announced its plan to acquire Arcellx, a biotechnology firm specializing in innovative CAR-T cell therapies. The acquisition deal is valued at approximately $7.8 billion and aims to bolster Gilead's presence in oncology. This strategic move is expected to close in the second quarter of 2026, subject to regulatory approvals.
2. Earnings Performance: The company reported a 5% increase in total product sales for Q4 2025, reaching $7.9 billion. Growth was primarily driven by strong sales in HIV and liver disease product lines. Analysts have forecasted Gilead’s adjusted earnings per share (EPS) for 2026 to range between $8.45 and $8.85, reflecting a positive financial outlook.
3. Regulatory Updates: Gilead received favorable news from the U.S. Food and Drug Administration (FDA), which accepted its New Drug Application (NDA) for lenacapavir. This twice-yearly injectable HIV-1 capsid inhibitor is intended as a pre-exposure prophylaxis (PrEP) treatment. The FDA’s decision to prioritize this application highlights the importance of innovative HIV therapies.
4. Market Sentiment: Investor sentiment has been optimistic due to Gilead’s recent strategic activities and the positive outlook within the biopharmaceutical sector. The stock’s outperformance relative to peers contributed to increased buying interest during the trading day.

Intraday Movements

Gilead's stock showed notable intraday volatility. After opening at $143.56, the price climbed quickly to an intraday high of $150.00, reflecting strong demand. However, some resistance emerged near this peak, resulting in a slight pullback before the session closed at $148.95. This trading pattern indicated a combination of profit-taking and sustained investor interest, driven by the positive news flow and growth prospects.

Conclusion

Overall, Gilead Sciences, Inc. had a strong trading day on February 27, 2026, closing significantly higher on the back of positive corporate developments and solid earnings results. The acquisition of Arcellx and the FDA’s acceptance of the lenacapavir NDA were key contributors to investor confidence. As Gilead continues to expand its therapeutic offerings and navigate regulatory pathways, it remains a significant player in the biopharmaceutical industry, with a market capitalization of approximately $182.5 billion as of the latest session.